Form 4: Zimmer Biomet Director Accrues Phantom Stock Units

Zimmer Biomet Holdings Director Maria Teresa Hilado accrued 344.036 phantom stock units under the company's deferred compensation plan.

Summary

• Maria Teresa Hilado, a Director at Zimmer Biomet Holdings, Inc. (ZBH), acquired 344.036 phantom stock units.
• These units were accrued on September 30, 2025, under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The conversion or exercise price for these units is 1-for-1, with a stated value of $98.1 per unit.
• Following this transaction, Ms. Hilado beneficially owns a total of 10,875.718 phantom stock units.
• The total includes 26.33 phantom stock units accrued on July 31, 2025, through the dividend reinvestment provision of the plan.
• The units are to be settled in cash through ten annual installments, beginning within sixty days after Ms. Hilado ceases service as a Director.

Sentiment

Score: 7

Explanation: The filing indicates a routine accrual of phantom stock units as part of a director's deferred compensation plan, which is generally viewed positively as it aligns the director's long-term interests with those of shareholders. It does not suggest any negative operational or financial issues.

Positives

• Director Maria Teresa Hilado increased her beneficial ownership of phantom stock units by 344.036 units, demonstrating continued alignment with shareholder interests.
• The accrual of units under a deferred compensation plan indicates a long-term commitment from the director to the company's performance.

Future Outlook

Phantom stock units will be settled in cash through ten annual installments, commencing within sixty days after the reporting person's cessation of service as a Director.

Industry Context

This filing represents a standard insider transaction related to director compensation, common across publicly traded companies. It does not inherently reflect broader industry trends but rather the company's specific compensation structure for its non-employee directors.

Comparison to Industry Standards

• Deferred compensation plans for non-employee directors, often including phantom stock units, are a common practice in the medical device and broader corporate sectors to align director interests with long-term shareholder value.
• The 1-for-1 conversion ratio for phantom stock units to common stock equivalent is standard for such plans.

Corporate Governance

Related Party Transactions

• Accrual of phantom stock units by a non-employee director under a company-sponsored deferred compensation plan.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of a director's long-term financial interests with the company's performance.

Next Steps

• Settlement of phantom stock units in cash over ten annual installments, commencing within sixty days after Maria Teresa Hilado ceases service as a Director.

Key Dates

Recommendation

This Form 4 filing details a routine accrual of phantom stock units by a non-employee director as part of a deferred compensation plan. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction primarily serves to align the director's long-term interests with shareholders, which is a positive but not a catalyst for a 'buy' or 'sell' decision. Therefore, a 'hold' recommendation is appropriate as the filing does not alter the fundamental investment thesis for ZBH.

Keywords

ZBH, Zimmer Biomet, Maria Teresa Hilado, Director, SEC Form 4, Phantom Stock Units, Deferred Compensation, Insider Transaction